Pancras C.W. Hogendoorn

Pancras C.W. Hogendoorn's AcademicInfluence.com Rankings

Philosophy

#7673

World Rank

#10918

Historical Rank

Logic

#4713

World Rank

#6037

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Pancras C.W. Hogendoorn's Degrees

PhD Pathology University of Amsterdam
Doctorate Medicine University of Amsterdam

Why Is Pancras C.W. Hogendoorn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Pancras C.W. Hogendoorn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial (2004) (1269)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours (2011) (835)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. (2014) (808)
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. (2005) (773)
Sarcoma Derived from Cultured Mesenchymal Stem Cells (2007) (628)
The clinical approach towards chondrosarcoma. (2008) (608)
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. (2009) (591)
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (437)
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. (2012) (414)
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? (2011) (372)
Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents (2011) (353)
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. (2007) (332)
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. (2005) (322)
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial (2016) (314)
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. (2005) (285)
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial (2015) (274)
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort (2019) (272)
The histopathological differential diagnosis of gastrointestinal stromal tumours (2001) (264)
Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data (2012) (258)
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2 (2009) (255)
Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (254)
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (2007) (240)
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets (2010) (236)
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† (2014) (235)
Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors (2009) (215)
Cartilaginous tumors: fast contrast-enhanced MR imaging. (2000) (206)
Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples (2011) (203)
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. (2008) (201)
Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. (2004) (200)
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. (2005) (199)
The clinical approach toward giant cell tumor of bone. (2014) (197)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom (2010) (194)
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. (2010) (186)
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. (2005) (186)
EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. (1999) (184)
Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional‐based study (2011) (175)
EWSR1-CREB1 and EWSR1-ATF1 Fusion Genes in Angiomatoid Fibrous Histiocytoma (2007) (175)
The NFATc2 Gene Is Involved in a Novel Cloned Translocation in a Ewing Sarcoma Variant That Couples Its Function in Immunology to Oncology (2009) (174)
Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. (2002) (171)
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. (2012) (168)
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours (2010) (168)
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease (2011) (167)
Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. (2011) (165)
A nation‐wide study comparing sporadic and familial adenomatous polyposis‐related desmoid‐type fibromatoses (2011) (161)
Aberrant Chemokine Receptor Expression and Chemokine Production by Langerhans Cells Underlies the Pathogenesis of Langerhans Cell Histiocytosis (2003) (160)
Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. (2002) (154)
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. (2011) (153)
Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families (2004) (153)
Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort (2010) (153)
Inactive Wnt/β‐catenin pathway in conventional high‐grade osteosarcoma (2010) (149)
Up-Regulation of PTHrP and Bcl-2 Expression Characterizes the Progression of Osteochondroma towards Peripheral Chondrosarcoma and Is a Late Event in Central Chondrosarcoma (2000) (147)
Frequent truncating mutations of STAG2 in bladder cancer (2013) (146)
Langerhans-cell histiocytosis 'insight into DC biology'. (2003) (146)
Adamantinoma of the long bones. A clinicopathological study of thirty-two patients with emphasis on histological subtype, precursor lesion, and biological behavior. (1994) (138)
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone (2010) (138)
Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities (1998) (136)
Dynamic contrast‐enhanced MR imaging of musculoskeletal tumors: Basic principles and clinical applications (1996) (134)
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. (2014) (134)
Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. (2007) (132)
Cathepsin K is the principal protease in giant cell tumor of bone. (2004) (131)
Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival (2016) (131)
Chondrosarcoma of the phalanx (1999) (131)
Sclerostin in Mineralized Matrices and van Buchem Disease (2009) (130)
Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model (2006) (130)
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. (2008) (128)
Imaging mass spectrometry statistical analysis. (2012) (127)
Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts) (2001) (121)
Pro‐inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T‐lymphocyte infiltration and affect tumour progression (2011) (119)
Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis (2005) (117)
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). (2013) (116)
Genome‐wide transcriptome analyses reveal p53 inactivation mediated loss of miR‐34a expression in malignant peripheral nerve sheath tumours (2010) (116)
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (2002) (115)
De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry (2015) (114)
Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad (2011) (112)
The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. (2007) (111)
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr (2017) (110)
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. (2009) (108)
Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma (1999) (108)
Multiple Statistical Analysis Techniques Corroborate Intratumor Heterogeneity in Imaging Mass Spectrometry Datasets of Myxofibrosarcoma (2011) (107)
The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target (2011) (107)
High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma. (2001) (107)
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. (2011) (106)
Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation (2007) (104)
Telomere‐associated proteins: cross‐talk between telomere maintenance and telomere‐lengthening mechanisms (2009) (103)
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell–macrophage lineage (2010) (102)
Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity (2010) (101)
Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma (2011) (100)
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. (2009) (99)
Murine chronic graft-versus-host disease as a model for lupus nephritis. (1988) (98)
Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma (2014) (97)
Molecular pathology of sarcomas: concepts and clinical implications (2009) (95)
Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas (2005) (95)
MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma (2013) (93)
Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma (2012) (91)
Pathology of primary malignant bone and cartilage tumours (2006) (90)
Mesenchymal stem cell transformation and sarcoma genesis (2013) (89)
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma (2013) (88)
Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas (2009) (86)
Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors (2015) (86)
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells (2011) (86)
ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. (2017) (85)
Lymphatics and bone. (2008) (85)
Prognostic factors in pulmonary metastasized high‐grade osteosarcoma (2009) (84)
Diagnosis and prognosis of chondrosarcoma of bone (2002) (83)
Molecular analysis of the INK4A/INK4A‐ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression (2004) (82)
Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma (2010) (81)
No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies (2009) (81)
Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma (2012) (80)
Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded tissues: a comparison of various antigen retrieval systems using microwave heating and proteolytic pre-treatments. (1995) (79)
Expression of Cell Cycle–Related Gene Products in Langerhans Cell Histiocytosis (2002) (78)
Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro (2008) (78)
Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. (1999) (77)
Reduced human leukocyte antigen expression in advanced‐stage Ewing sarcoma: implications for immune recognition (2009) (77)
Expression Profiling of t(12;22) Positive Clear Cell Sarcoma of Soft Tissue Cell Lines Reveals Characteristic Up-Regulation of Potential New Marker Genes Including ERBB3 (2004) (77)
Multiple Osteochondromas: Clinicopathological and Genetic Spectrum and Suggestions for Clinical Management (2004) (77)
Incidence of Biopsy-Proven Bone Tumors in Children: A Report Based on the Dutch Pathology Registration "PALGA" (2008) (77)
Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C (2004) (77)
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways (2009) (76)
The extracellular matrix in pathology. (1988) (76)
Chondroma and chondrosarcoma of the larynx (2004) (76)
Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. (2010) (76)
The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). (2012) (75)
Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma (2011) (75)
Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. (1996) (74)
Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. (2004) (73)
Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. (2005) (73)
Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors (2009) (72)
Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors (2009) (71)
Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT (2012) (70)
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis (2012) (69)
Genome‐wide analyses on high‐grade osteosarcoma: Making sense of a genomically most unstable tumor (2013) (69)
No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas. (2010) (69)
Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches (2012) (68)
Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities (1998) (68)
Clear cell sarcoma of the stomach (2002) (68)
Aggressive angiomyxoma: a clinicopathological and immunohistochemical study of 11 cases with long-term follow-up (2005) (66)
Adamantinoma of the Long Bones: Keratin Subclass Immunoreactivity Pattern with Reference to Its Histogenesis (1993) (64)
GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma (2014) (63)
Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma. (2000) (63)
Cytogenetic analysis of adamantinoma of long bones: further indications for a common histogenesis with osteofibrous dysplasia. (1997) (63)
Low-grade chondrosarcoma of long bones treated with intralesional curettage followed by application of phenol, ethanol, and bone-grafting. (2012) (63)
Amplification of 17p11.2∼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma (2002) (62)
Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results (2003) (61)
Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix (2009) (60)
A short-term in vivo model for giant cell tumor of bone (2011) (60)
Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma (2005) (59)
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. (2012) (59)
Late Malignant Transformation of a Benign Giant-Cell Tumor of Bone. A Case Report* (1997) (58)
Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis (1998) (57)
The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials (2008) (57)
A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. (2004) (56)
Soft Tissue Tumours of the Retroperitoneum (2000) (55)
Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy (2014) (55)
Adenocarcinoma arising within a tailgut cyst: clinicopathological description and follow up of an unusual case. (1999) (54)
Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens. (2012) (54)
Malignant progression in multiple enchondromatosis (Ollier's disease): an autopsy-based molecular genetic study. (2000) (54)
Pathogenesis of experimental lupus nephritis: a role foranti‐basement membrane and anti‐tubular brush border antibodiesin murine chronic graft‐versus‐host disease (1990) (53)
Mutation screening of EXT1 and EXT2 by direct sequence analysis and MLPA in patients with multiple osteochondromas: splice site mutations and exonic deletions account for more than half of the mutations (2005) (53)
Tumor-Associated Macrophages Are Related to Volumetric Growth of Vestibular Schwannomas (2013) (53)
Benign Cartilaginous Tumors of Bone: From Morphology to Somatic and Germ-line Genetics (2009) (52)
Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes (2015) (52)
MRI of adamantinoma of long bones in correlation with histopathology. (2004) (52)
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. (2008) (52)
Tiling resolution array‐CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients (2011) (51)
Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours (2010) (50)
Langerhans cell histiocytosis: A pathologic combination of oncogenesis and immune dysregulation (2004) (50)
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup (2012) (49)
Lymph node staging standards in gastric cancer. (1995) (49)
cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade (2005) (49)
Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas (2012) (48)
Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array‐CGH analysis (2009) (48)
The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. (2012) (48)
Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. (2005) (47)
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (2007) (47)
Running GAGs: myxoid matrix in tumor pathology revisited (2009) (47)
Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: a population-based study. (2009) (47)
Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets. (2013) (47)
Distinct histological features characterize primary angiosarcoma of bone (2011) (47)
Clinico-histologic parameters of osteosarcoma patients with late relapse. (2006) (46)
Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. (2009) (46)
Sdhd and Sdhd/H19 Knockout Mice Do Not Develop Paraganglioma or Pheochromocytoma (2009) (46)
Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. (2006) (46)
Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. (2004) (46)
A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone (2010) (45)
IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis (2011) (45)
Array‐comparative genomic hybridization of central chondrosarcoma (2006) (44)
Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes. (2001) (44)
A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma (1999) (44)
The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease (2012) (44)
Intermediate grade osteosarcoma and chondrosarcoma arising in an osteochondroma. A case report of a patient with hereditary multiple exostoses. (2002) (44)
Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. (2002) (43)
Hemicortical allograft reconstruction after resection of low-grade malignant bone tumours. (2002) (43)
Primary synovial sarcoma of the heart: a cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH of a case with a complex karyotype (2004) (42)
MR imaging based strategies in limb salvage surgery for osteosarcoma of the distal femur (1997) (42)
mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts (2011) (41)
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (41)
MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance (2007) (41)
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (41)
Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. (2016) (40)
The immunophenotype of osteoclasts and macrophage polykaryons (2011) (40)
Myxoid tumours of soft tissue: the so‐called myxoid extracellular matrix is heterogeneous in composition (2008) (40)
Erratum: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Concensus Conference of 20-21 March 2004, under the auspices of ESMO (Annals of Oncology (2005) vol. 16 (566-578)) (2005) (40)
Characterization and in vivo transfer of nephritogenic autoantibodies directed against dipeptidyl peptidase IV and laminin in experimental lupus nephritis. (1990) (39)
Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone (2012) (38)
The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting (2005) (38)
Genome-wide analysis of Ollier disease: Is it all in the genes? (2011) (37)
Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin (2015) (37)
Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival (2016) (37)
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. (2008) (36)
Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines. (2006) (36)
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. (2014) (36)
Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter (2012) (36)
Detection of areas with viable remnant tumor in postchemotherapy patients with Ewing's sarcoma by dynamic contrast-enhanced MRI using pharmacokinetic modeling. (2000) (35)
Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas (2012) (35)
Solitary fibrous tumour: the emerging clinicopathologic spectrum of an entity and its differential diagnosis (2004) (35)
Recurrent Chromosome 22 Deletions in Osteoblastoma Affect Inhibitors of the Wnt/Beta-Catenin Signaling Pathway (2013) (34)
Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment (2012) (34)
DNA aberrations in the epithelial cell component of adamantinoma of long bones. (1995) (34)
Aven‐mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma (2015) (34)
MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response" randomization. (2013) (34)
The First European Interdisciplinary Ewing Sarcoma Research Summit (2012) (34)
Malignant astrocytoma‐derived region of common amplification in chromosomal band 17p12 is frequently amplified in high‐grade osteosarcomas (1997) (33)
Multiparameter DNA flow‐sorting demonstrates diploidy and SDHD wild‐type gene retention in the sustentacular cell compartment of head and neck paragangliomas: chief cells are the only neoplastic component (2004) (33)
Chondroblastic osteosarcoma: characterisation by gadolinium-enhanced MR imaging correlated with histopathology (1998) (33)
Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes (2009) (33)
Dedifferentiated Adamantinoma With Revertant Mesenchymal Phenotype (2003) (33)
Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways (2007) (33)
Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo (2011) (32)
Antibodies to purified renal tubular epithelial antigens contain activity against laminin, fibronectin, and type IV collagen. (1988) (31)
Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours. (1999) (31)
Distribution of extracellular matrix components in adamantinoma of long bones suggests fibrous-to-epithelial transformation. (1997) (31)
Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice[S] (2013) (30)
The clinical use of biomarkers as prognostic factors in Ewing sarcoma (2012) (30)
Retroperitoneal extraskeletal osteosarcoma (2001) (30)
Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup (2012) (30)
MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation (2015) (29)
HSPG-Deficient Zebrafish Uncovers Dental Aspect of Multiple Osteochondromas (2012) (29)
Tumor Biology of Vestibular Schwannoma: A Review of Experimental Data on the Determinants of Tumor Genesis and Growth Characteristics (2015) (29)
The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study (2018) (28)
Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. (2007) (28)
Osteosarcoma Models: From Cell Lines to Zebrafish (2012) (28)
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option (2010) (28)
ALK+ histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. (2021) (27)
Breakpoint characterization of large deletions in EXT1 or EXT2 in 10 Multiple Osteochondromas families (2011) (26)
TGF‐β1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone (2006) (26)
A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). (1999) (26)
Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype (2015) (26)
M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma (2018) (25)
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study (2017) (24)
Chondromyxoid fibroma resembles in vitro chondrogenesis, but differs in expression of signalling molecules (2005) (24)
Smooth muscle actin expression in primary bone tumours (2012) (24)
Heterogeneous and complex rearrangements of chromosome arm 6q in chondromyxoid fibroma: delineation of breakpoints and analysis of candidate target genes. (2010) (23)
Imaging mass spectrometry-based molecular histology differentiates microscopically identical and heterogeneous tumors. (2013) (23)
Cartilage-forming tumours of bone and soft tissue and their differential diagnosis (2001) (22)
Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi (2007) (22)
Non‐ossifying fibroma: A RAS‐MAPK driven benign bone neoplasm† (2019) (22)
A ΔRaf1–ER‐inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures (2011) (22)
Results of Diagnostic Review in Pediatric Bone Tumors and Tumorlike Lesions (2008) (21)
MAPIE vs MAP as postoperative chemotherapy in patients with a poor response to preoperative chemotherapy for newly-diagnosed osteosarcoma: results from EURAMOS-1 (Paper 032) (2014) (20)
Ring chromosome 4 as the sole cytogenetic anomaly in a chondroblastoma: a case report and review of the literature. (1998) (20)
Scale-invariant segmentation of dynamic contrast-enhanced perfusion MR images with inherent scale selection (2002) (20)
The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone (2011) (19)
Central high-grade osteosarcoma of bone: Diagnostic and genetic considerations (2005) (19)
Late sarcoma development after curettage and bone grafting of benign bone tumors. (2011) (19)
Prognosis of Primary and Recurrent Chondrosarcoma of the Rib (2016) (19)
Multicolor fluorescence in situ hybridization analysis of a synovial sarcoma of the larynx with a t(X;18)(p11.2;q11.2) and trisomies 2 and 8. (2004) (19)
Development of progressive glomerulosclerosis in experimental chronic serum sickness. (1990) (19)
Epidemiology of primary bone tumors and economical aspects of bone metastases (2010) (19)
The cytotoxic effect of phenol and ethanol on the chondrosarcoma-derived cell line OUMS-27: an in vitro experiment. (2008) (18)
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways (2009) (18)
The molecular and cellular basis of exostosis formation in hereditary multiple exostoses (2009) (18)
Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia (2011) (18)
Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma (2010) (17)
A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient (2004) (17)
Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients (2012) (17)
Limited Rescue of Osteoclast‐Poor Osteopetrosis After Successful Engraftment by Cord Blood From an Unrelated Donor (2005) (17)
Identification of an EWS-pseudogene using translocation detection by RT-PCR in Ewing's sarcoma. (1995) (16)
Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis (2009) (16)
Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation (2011) (16)
The role of noncartilage‐specific molecules in differentiation of cartilaginous tumors (2007) (16)
Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial (2019) (15)
Local recurrence of a phyllodes tumour of the breast presenting with widespread differentiation to a telangiectatic osteosarcoma. (1998) (15)
Neoadjuvant denosumab for extensive giant cell tumor in os ischium —a case report (2015) (15)
Thromboembolic involvement and its possible pathogenesis in COVID-19 mortality: lesson from post-mortem reports. (2021) (15)
Chondrosarcoma is not characterized by detectable telomerase activity (2001) (15)
Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis (2014) (15)
Basic fibroblast growth factor and fibroblastic growth factor receptor-1 may contribute to head and neck paraganglioma development by an autocrine or paracrine mechanism. (2007) (15)
Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability. (2007) (14)
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup (2019) (14)
Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones (2012) (14)
Paratesticular desmoplastic small round cell tumour: an unusual tumour with an unusual fusion; cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH (2012) (14)
Carcinoid tumor of the jugulo-tympanic region. (1996) (14)
Reclassification and subtyping of so-called malignant fibrous histiocytoma of bone: comparison with cytogenetic features (2011) (14)
Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis (2014) (14)
Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma (2019) (14)
Array-Comparative Genomic Hybridization of Central Chondrosarcoma IdentificationofRibosomalProteinS6andCyclin-DependentKinase4asCandidateTargetGenesforGenomicAberrations (2006) (14)
Translocation (11;22)(q24;q12) in a small cell tumor of the thigh in a 2-year-old boy: immunohistology, cytogenetics, molecular genetics, and review of the literature. (1999) (13)
Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation (2020) (13)
Absence of Epstein-Barr virus (EBV) in a gastrointestinal stromal cell tumour (GIST) in an adult human immunodeficiency virus-seropositive patient with past EBV infection. (1997) (13)
Nikolay Ivanovich Pirogov (1810–1881): A pioneering Russian surgeon and medical scientist (2018) (13)
‘The chicken or the egg?’ dilemma strikes back for the controlling mechanism in chordoma# (2012) (13)
A balanced t(5;17) (p15;q22-23) in chondroblastoma: frequency of the re-arrangement and analysis of the candidate genes (2009) (13)
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. (2021) (12)
Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy (2016) (12)
[From gene to disease; hereditary multiple exostoses]. (2002) (11)
Anti-inflammatory M 2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors (2010) (10)
Glomerular capillary wall charge and antibody binding in passive Heymann nephritis. (1988) (10)
Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma (2018) (10)
Skin metastases of osteogenic sarcoma: a case report with review of the literature. (1997) (10)
Primary intraosseous manifestation of Rosai-Dorfman disease: 2 cases and review of literature. (2014) (9)
[Adamantinoma of the long bones: an anatomo-clinical review and its relationship with osteofibrous dysplasia]. (2001) (9)
Mesenchymal stromal cells of osteosarcoma patients do not show evidence of neoplastic changes during long-term culture (2015) (9)
Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Res Imaging (2002) (9)
Nikolay Ivanovich Pirogov (1810–1881): Anatomical research to develop surgery (2019) (9)
Metastasis of breast carcinoma to a primary mucinous cystadenocarcinoma of the ovary. (1994) (9)
Increased dynamin expression precedes proteinuria in glomerular disease (2018) (9)
How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone? (1998) (9)
Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1 (2015) (9)
Cancer biology and genomics: translating discoveries, transforming pathology (2011) (9)
G2M arrest, blocked apoptosis, and low growth fraction may explain indolent behavior of head and neck paragangliomas. (2003) (8)
Bioorthogonally Applicable Fluorescence Deactivation Strategy for Receptor Kinetics Study and Theranostic Pretargeting Approaches (2018) (8)
Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: A randomised controlled trial of the European Osteosarcoma Intergroup (ISRCTN 86294690). (2003) (8)
[Practice guideline 'Diagnostic techniques for soft tissue tumours and treatment of soft tissue sarcomas (revision)']. (2005) (8)
New indicators and indexes for benchmarking university–industry–government innovation in medical and life science clusters: results from the European FP7 Regions of Knowledge HealthTIES project (2019) (8)
Possible effects of EXT2 on mesenchymal differentiation - lessons from the zebrafish (2014) (8)
Molecular identification of a partial hydatidiform mole. (1997) (8)
Hematopoietic Tumors Primarily Presenting in Bone. (2017) (7)
A translocation t(6;14) in two cases of leiomyosarcoma: Molecular cytogenetic and array-based comparative genomic hybridization characterization. (2015) (7)
Prenatal detection of orbital rhabdomyosarcoma. (2005) (7)
Zebrafish as a model for human osteosarcoma. (2014) (7)
Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis (2021) (7)
MRI appearances of atypical cartilaginous tumour/grade I chondrosarcoma after treatment by curettage, phenolisation and allografting: recommendations for follow-up. (2016) (7)
High prevalence of autoimmune disease in the rare inflammatory bone disorder sternocostoclavicular hyperostosis: survey of a Dutch cohort (2017) (7)
A novel rat mesangial matrix protein, MMP-50/100, involved in mesangial glomerulopathies. (1995) (6)
The histopathological differential diagnosis of mesenchymal tumours of the skin (2005) (6)
Re. Review Article entitled ‘The neoplastic pathogenesis of solitary and multiple osteochondromas’ (2000) (6)
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 cohort (2018) (6)
Nuclear factor-κB activation in primary lymphoma of bone (2013) (6)
Molecular genetics of Ewing sarcoma, model systems and finding novel (immuno-) therapeutic targets (2018) (6)
Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma (2019) (5)
Automation of Technology for Cancer Research. (2016) (5)
Antigen size influences the type of glomerular pathology in chronic serum sickness. (1993) (5)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies (2008) (5)
Glomerulopathy induced by a single monoclonal autoantibody against GP330. (1995) (5)
Does parosteal liposarcoma differ from other atypical lipomatous tumors/well-differentiated liposarcomas? A molecular cytogenetic study using combined multicolor COBRA-FISH karyotyping and array-based comparative genomic hybridization. (2007) (5)
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas (2013) (5)
Chapter 1 – Epidemiology of primary bone tumors and economical aspects of bone metastases (2015) (5)
The role of non cartilage-specific molecules in differentiation of cartilaginous tumours: lessons from chondroblastoma and chondromyxoid fibroma (2010) (5)
CXCR4 signaling is controlled by immobilization at the plasma membrane. (2016) (4)
The diagnostic utility of DOG1 expression in KIT-negative GIST (2008) (4)
Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy (2019) (4)
Segmentation of bone tumor in MR perfusion images using neural networks and multiscale pharmacokinetic features (2000) (4)
Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases. (2021) (4)
694 EORTC 62011: phase II trial of brostallicin for soft tissue sarcoma (2003) (4)
Maffucci syndrome: A genome‐wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases (2011) (4)
Glomerular permeability is not affected by heparan sulfate glycosaminoglycan deficiency in zebrafish embryos. (2019) (4)
Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma (2017) (4)
EURAMOS-1 study : Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma (2012) (4)
BCRP expression in schwannoma, plexiform neurofibroma and MPNST (2017) (4)
Pitfalls in pathology of soft tissue sarcomas. (2004) (4)
Molecular genetics of chondroid tumours (2014) (4)
Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas: An International Multicenter Study of 318 Cases. (2020) (3)
Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas: An International Multicenter Study of 318 Cases. (2020) (3)
NTRK fusions are extremely rare in bone tumours (2021) (3)
An update of diagnostic strategies using molecular genetic and magnetic resonance imaging techniques for musculoskeletal tumors. (2000) (3)
The adapter protein Myd88 plays an important role in limiting mycobacterial growth in a zebrafish model for tuberculosis (2021) (3)
The development of Russian Medicine in the Petrine era and the role of Dutch doctors in this process (2019) (3)
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study. (2010) (3)
Phenol levels during intralesional curettage and local adjuvant treatment of benign and low-grade malignant bone tumours (2012) (3)
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial) (2022) (3)
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. (2010) (3)
Survival after recurrent osteosarcoma: Data from three European Osteosarcoma Intergroup (EOI) randomized controlled (2008) (3)
Abstract #5680: Impact of EWS-FLI1 fusion type on disease progression in Ewing's sarcoma: Prospective results from the cooperative Euro-E.W.I.N.G.99 trial (2009) (2)
Women in healthcare in Imperial Russia: The contribution of the surgeon Nikolay I Pirogov (2019) (2)
Adamantinoma of long bones : current perspectives on clinical behaviour, histology and histogenesis (1996) (2)
Response to Fadeel and Henter: Langerhans cell histiocytosis: a combination of carcinogenesis and inflammation (2003) (2)
The more it hurts, the better it works? Chemotherapy toxicity as a predictor of outcome from osteosarcoma: a report from the European Osteosarcoma Intergroup. (2008) (2)
Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone (2022) (2)
[Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor]. (2003) (2)
Molecular imaging of multidrug resistance in an orthotopic model of osteosarcoma (2006) (2)
The Journal of Pathology 2008 Jeremy Jass Prize for Research Excellence in Pathology (2009) (2)
Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology. (2011) (2)
Pathogenesis of glomerulonephritis: experimental models revisited. (1991) (2)
The histopathological diVerential diagnosis of gastrointestinal stromal tumours (2001) (2)
Segmentation of Dynamic Contrast-Enhanced MR-Images of Post Chemotherapy Ewing's Sarcoma with a Pharmacokinetic Model and a Neural Network (1999) (2)
Pathology of soft tissue sarcomas with emphasis on molecular diagnostic techniques (2003) (2)
Chondromyxoid fibroma resembles in vitro chondrogenesis (2005) (2)
The role of Dutch representatives in the development of medicine in Russia from the 9th to the 13th century (2019) (2)
Aromatase inhibition in patients with recurrent and/or metastatic chondrosarcoma (CS) (2008) (2)
Dasatinib Src inhibitor selectively triggers apoptosis and loss of invasive potential in human osteosarcoma cells (2016) (1)
Desmoplastic fibroma of bone: An immunohistochemical study on 13 cases including beta-catenin expression and mutational analysis for catenin (2005) (1)
A multistep tumour progression model (2005) (1)
Genome-wide transcriptome analysis of nerve sheath tumors (2006) (1)
ch ap te r 7 reduced leukocyte cholesteryl ester transfer protein expression in acute coronary syndromes (2009) (1)
The Molecular Mechanisms of Gradient Sensing by CXCR4 (2014) (1)
3.P.18 RISK FACTORS FOR LOCAL RECURRENCE IN GIANT CELL TUMOUR (GCT) OF THE LONG BONE (2010) (1)
Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone (2012) (1)
Advances in bone and cartilaginous tumours (2005) (1)
Expression of HER 2 / Neu ( HER 2 ) and EGFR In Osteosarcoma ( Os ) (2003) (1)
693 Does increasing dose intensity in patients with operable osteosarcoma of the extremity improve outcome? A randomised controlled trial of the European Osteosarcoma Intergroup (EOI) (2003) (1)
Bone: Chondromyxoid fibroma (2011) (1)
[New insights in the classification of soft tissue tumors]. (2002) (1)
Automated microinjection of cell-polymer suspensions for high throughput quantitiative cancer invasion screens. (2011) (1)
Bone & Soft Tissue (2011) (1)
Mutations in the heparan sulfate backbone elongating enzymes EXT1 and EXT2 have no major effect on endothelial glycocalyx and the glomerular filtration barrier (2022) (1)
Case Report: Asymptomatic COVID-19 patient with a subtle hypercoagulable state and fluctuating D-dimer level (2021) (1)
BISPHOSPHONATE TREATMENT OF GIANT CELL TUMOUR OF BONE (2011) (1)
Soft tissue sarcomas: introduction to the Virchows Archiv review issue (2010) (1)
Investigation of potential chromosomal abnormalities in the lesional cells of Langerhans cell histiocytosis (2007) (1)
PRAME: A target antigen for immunotherapy in Ewing’s sarcoma (2005) (1)
Bones and Joints Cancer: Pathology and Genetics (2019) (1)
The clinical impact of molecular techniques on diagnostic pathology of soft tissue and bone tumours (2012) (1)
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma (2013) (1)
Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group. (2011) (0)
6.5-YEARS CLINICAL FOLLOW-UP OF NINETY PATIENTS WITH LOW-GRADE CENTRAL CHONDROSARCOMA OF LONG BONES, TREATED WITH INTRALESIONAL CURETTAGE FOLLOWED BY PHENOL, ETHANOL AND BONE GRAFTING (2012) (0)
3.P.40 TOWARDS GENETIC UNDERSTANDING OF OLLIER DISEASE (2010) (0)
Parent-of-origin-dependent inheritance in SDHD-linked paragangliomas (2012) (0)
Novel translocation variant in ewing sarcoma involving the NFATc2 gene (2010) (0)
SARCOMA DEVELOPMENT AFTER CURETTAGE AND BONE GRAFTS OF BENIGN BONE LESIONS (2012) (0)
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial) (2022) (0)
clinical practice guidelines Bone sarcomas : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up (2010) (0)
Malignant Fibrous Histiocytoma and Fibrosarcoma of Bone in 2011: What's New? (2011) (0)
Faculty Opinions recommendation of Visualizing extravasation dynamics of metastatic tumor cells. (2010) (0)
Nikolay Ivanovich Pirogov as an innovator in anatomy, surgery, and anaesthesiology. Part II (2020) (0)
Book Review—Diagnostic pathology: bone, 2nd edition (2018) (0)
Network to promote research into uncommon in adults and children: pathology, biology and genetics of bone tumors (2006) (0)
Chapter 8 REDUCED LEUKOCYTE CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION IN ACUTE CORONARY SYNDROMES (2008) (0)
Expression profiling of osteosarcoma and its putative progenitor cells to identify pathways involved in tumorigenesis (2007) (0)
3.P.06 HAEMANGIOPERICYTOMA OF BONE: REAL OR IMAGINED? (2010) (0)
Understanding the Molecular Mechanism of Gradient Sensing (2013) (0)
Mesenchymal stromal cells derived from osteosarcoma patients do not transform during long-term culture (2014) (0)
Expression profiling of peripheral chondrosarcoma progression: towards molecular understanding for diagnostic tools (2002) (0)
T cell-mediated immunotherapy in Ewing's sarcoma with a focus on tumor antigen PRAME (2003) (0)
Cover Feature: Bioorthogonally Applicable Fluorescence Deactivation Strategy for Receptor Kinetics Study and Theranostic Pretargeting Approaches (ChemBioChem 16/2018) (2018) (0)
Hereditary Background in Bone and Soft-Tissue Tumours (2002) (0)
A phase II study of Gefitinib for patients with HER-1 expressing advanced synovial sarcoma refractory to doxorubicin-based chemotherapy. (2008) (0)
Abstract 3780: Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in osteosarcoma cells (2015) (0)
In reply. (2014) (0)
275 Taxanes in angiosarcomas (2009) (0)
3.O.10 INCIDENCE, PREDICTIVE FACTORS AND PROGNOSIS OF CENTRAL CHONDROSARCOMA IN PATIENTS WITH OLLIER DISEASE AND MAFFUCCI SYNDROME; REPORT OF 133 PATIENTS (2010) (0)
7.P.28 FACTORS DETERMINING SURVIVAL AFTER RESECTION OF PULMONARY METASTASIS OF HIGH GRADE OSTEOSARCOMA (2010) (0)
EstrogenSignaling Is Active in CartilaginousTumors : Implications for Antiestrogen Therapy as Treatment Option ofMetastasized or Irresectable Chondrosarcoma (2005) (0)
Leader Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours (1999) (0)
Non-Hodgkin lymphoma of bone of the femur and humerus: a case report and review of the literature (2021) (0)
New indicators and indexes for benchmarking university-industry-government innovation in medical and life science clusters: Results from European FP7 Regions of Knowledge project HealthTIES (2019) (0)
3.O.05 HIGH-GRADE ANGIOSARCOMA OF BONE: A CLINICOPATHOLOGICAL STUDY OF 64 CASES (2010) (0)
Soft tissue pathology (2006) (0)
Diagnosis and Treatment of Borderline Lesions (2002) (0)
Alternative splicing of HDMX predicts p53 inactivation and bad prognosis (2011) (0)
Assessment of the influence of preoperative chemotherapy in patients with osteosarcoma by dynamic contrast-enhanced MRI using pharmacokinetic modeling (2001) (0)
Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy (2014) (0)
[Molecular biology diagnosis of tumors of the musculoskeletal system]. (1997) (0)
Molecular Mechanisms of Gradient Sensing in Ewing's Sarcoma Cells (2012) (0)
2011 Jeremy Jass Prize for Research Excellence in Pathology (2012) (0)
F.139. Expression and Functional Relevance of cFLIP, PI-9 and Caspase 8 in Ewing's Sarcoma: Implications for Immunotherapy (2006) (0)
Tumor immunity and immunosurveillance (PP-093) (2010) (0)
rapeutic Targets in Intimal Sarcoma (2010) (0)
Balanced and Unbalanced Rearrangement of Chromosome Arm 6q in Chondromyxoid Fibroma (CMF): Delineation of Breakpoints and Analysis of Candidate Target Genes (2009) (0)
Molecular and genetic aspects and matrix charactereisation of myxoid soft tissue tumours (2009) (0)
Nikolay Ivanovich Pirogov: Forerunner, co-founder and Inspector-General of the Red Cross (2020) (0)
Reviewers for Cellular Oncology in 2008 (2009) (0)
Chondrosarcoma and Its Precursors (2007) (0)
Heparan sulphate upholds osteoblastic lineage (2012) (0)
Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma (2017) (0)
Estrogen signaling as a target for chondrosarcoma treatment (2007) (0)
Chapter 6 Gene expression of head and neck paragangliomas (2012) (0)
EXT and HSPGs in osteochondromas and peripheral chondrosarcomas (0)
Medical instruments in Imperial Russia: from a blacksmith to a factory for medical instruments, headed by a leading surgeon N.L. Bidloo (2021) (0)
Abstract 4295: High-throughput screening of osteosarcoma progression: A zebrafish model (2011) (0)
Heterogeneous and Complex Rearragements of the Long Arm of Chromosome 6 in Chondromyxoid Fibroma (2010) (0)
Ultrastructural Organisation of Cartilage in Proteoglycan-Deficient Zebrafish Mutants (2010) (0)
The Dutchman Herman Boerhaave and the Russian Nikolay Ivanovich Pirogov are brilliant medical scientists, whose remembrance will be eternal (2020) (0)
This is a repository copy of Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation (2018) (0)
7.P.62 ISOLATED LUNG PERFUSION (ILUP) WITH MELPHALAN IN PATIENTS WITH PULMONARY METASTASES: PRELIMINARY DATA (2010) (0)
European Musculo-Skeletal Oncology Society Meeting, 24 & 25 May 2001, Pamplona: Abstracts and Poster Presentation and Nurses Symposium (2001) (0)
3.O.09 VIVO AND IN VITRO EFFECTS OF BISPHOSPHONATE TREATMENT ON GIANT CELL TUMOUR OF BONE (2010) (0)
23 Assessment of molecular determinants of development and treatment efficacy in radiation induced sarcoma (RIS) — eortc translational research project 01/01 (2006) (0)
Molecular Genetics of Multiple Osteochondromas (2016) (0)
Impaired GARNL4 and BCLAF1 expression: novel oncogenic mechanism in balanced rearrangement in chondromyxoid fibroma? (2008) (0)
Immunopathologic Features of Inflammatory Coats Disease (2005) (0)
5 Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis (2008) (0)
Abstract 5128: Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data (2012) (0)
Bone & Soft Tissue (2010) (0)
3 EGFR and ERBB 2 expression in sarcomas : the search for new treatment options (2009) (0)
Highlights of the professional activities of Nikolay Ivanovich Pirogov before and after his professoriate in Saint Petersburg (1841–1860). Part I (2020) (0)
Taxanes in angiosarcomas (2009) (0)
P41: Array-comparative genomic hybridisation identifies specific rearrangement in atypical lipomatous tumour/well-differentiated liposarcoma and improves the diagnosis (2005) (0)
Molecular tumor pathology and tumor genetics (2003) (0)
Cancer of Bones and Joints (2018) (0)
7.P.39 A VARIANT EWING SARCOMA: NOVEL TRANSLOCATION INVOLVING THE NFATC2 GENE IN MULTIPLE CASES (2010) (0)
Array-CGH Analysis of Chondromyxoid Fibroma complementary to conventional cytogenetics points to recurrent involvement of chromosomal region 6q23 (2006) (0)
Chromosomal-specific rearrangements of bone and soft tissue tumors which are not cytogenetically characterized: a multicolor fluorescence in situ hybridization approach (2001) (0)
Signal transduction pathways in skeletal differentiation as therapeutic targets for high grade central osteosarcoma (2008) (0)
Histopathological Characteristics of Clinical Growth in Sporadic Vestibular Schwannomas (2012) (0)
Co-existence of lung carcinoma metastasis and enchondroma in the femur of a patient with Ollier disease (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Pancras C.W. Hogendoorn?

Pancras C.W. Hogendoorn is affiliated with the following schools: